EirGenix Makes Progress With Trastuzumab Biosimilar

Company Plans To Submit Filings To Both FDA and EMA

 
• By Akriti Seth
  
clinical trials
EirGenix sees positive Phase III results for its Herceptin biosimilar • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products